Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average Price Target from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $56.33.

AGIO has been the subject of several recent analyst reports. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th.

Agios Pharmaceuticals Stock Up 2.2 %

NASDAQ:AGIO opened at $35.90 on Friday. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 3.16 and a beta of 0.87. The company’s 50 day moving average price is $46.77 and its 200-day moving average price is $45.50.

Insider Activity at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.93% of the stock is owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its position in shares of Agios Pharmaceuticals by 13.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company’s stock worth $9,622,000 after purchasing an additional 27,193 shares during the last quarter. TD Asset Management Inc increased its holdings in shares of Agios Pharmaceuticals by 34.6% in the 2nd quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company’s stock valued at $9,076,000 after acquiring an additional 54,054 shares during the period. North Star Asset Management Inc. purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $216,000. Candriam S.C.A. acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at $13,922,000. Finally, Acadian Asset Management LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth approximately $37,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.